Latest News
News Functions
Additional Functions
7 July 2015
Oasmia Pharmaceutical AB
Oasmia Pharmaceutical Files a Registration Statement on Form F-1/A for its Proposed Public Offering and an Application with NASDAQ for a US Listing and Announces Investor Roadshow
Oasmia Pharmaceutical AB
Oasmia Pharmaceutical Launches US Brand and Sales Platform
4 June 2015
Oasmia Pharmaceutical AB
Year-end report for the fiscal year May 2014 – April 2015
29 May 2015
Oasmia Pharmaceutical AB
Changes in Oasmia’s Board of Directors and Management
Oasmia Pharmaceutical AB
Communiqué from Oasmia’s Extraordinary General Meeting 2015
7 May 2015
Oasmia Pharmaceutical AB
Oasmia gives notice of Extraordinary General Meeting
Oasmia Pharmaceutical AB
Notice of Extraordinary General Meeting in Oasmia Pharmaceutical AB (publ)
24 April 2015
Oasmia Pharmaceutical AB
Results from Oasmia’s Phase III study will be presented at ASCO
20 April 2015
Oasmia Pharmaceutical AB
Oasmia’s lead cancer product Paclical(r) receives market approval in the Russian Federation
Oasmia Pharmaceutical AB
Oasmia’s lead cancer product Paclical® receives market approval in the Russian Federation
5 March 2015
Oasmia Pharmaceutical AB
Interim report for the period May 2014 – January 2015
17 February 2015
Oasmia Pharmaceutical AB
Oasmia initiates clinical Phase II study with Doxophos Vet for the treatment of canine lymphoma
30 December 2014
Oasmia Pharmaceutical AB
Nxt2b extends loan to Oasmia
Oasmia Pharmaceutical AB
Publication of change in the total number of shares and votes in Oasmia
Oasmia Pharmaceutical AB
Publication of change in the total number of shares and votes in Oasmia
Oasmia Pharmaceutical AB
Oasmia receives a new MSEK 20 bank loan
18 December 2014
Oasmia Pharmaceutical AB
Oasmia’s Chairman of the Board buys shares
17 December 2014
Oasmia Pharmaceutical AB
Oasmia change to Mid Cap segment at Nasdaq Stockholm
12 December 2014
Oasmia Pharmaceutical AB
Final result of Oasmia’s rights issue
10 December 2014
Oasmia Pharmaceutical AB
Preliminary result of Oasmia’s rights issue
4 December 2014
Oasmia Pharmaceutical AB
Prospectus addendum regarding Oasmia Pharmaceutical’s rights issue is now available
Oasmia Pharmaceutical AB
Interim report for the period May – October 2014
17 November 2014
Oasmia Pharmaceutical AB
Prospectus, including new financial information, regarding Oasmia Pharmaceutical’s rights issue is now available
11 November 2014
Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB announces a fully committed and underwritten rights issue of approximately SEK 176 million.
21 October 2014
Oasmia Pharmaceutical AB
Oasmia’s lead human oncology product Paclical shows a positive risk/benefit profile versus standard treatment in pivotal phase III clinical study
1 October 2014
Oasmia Pharmaceutical AB
Communiqué from Oasmia’s Annual General Meeting 2014
30 September 2014
Oasmia Pharmaceutical AB
Oasmia receives a new MSEK 40 bank loan
12 September 2014
Oasmia Pharmaceutical AB
Oasmia considers secondary listing on NASDAQ USA
5 September 2014
Oasmia Pharmaceutical AB
Interim report for the period May – July 2014
1 September 2014
Oasmia Pharmaceutical AB
Correction of notice regarding notice of Annual General Meeting